Back to search results

FAST-MRI Study for Liver Cancer Screening

This observational study, called FAST-MRI, is comparing a new, shorter MRI (Magnetic Resonance Imaging) scan to ultrasound (US) for screening liver cancer (Hepatocellular Carcinoma or HCC) in people with liver cirrhosis. Researchers want to see if this abbreviated MRI is better at finding liver cancer than ultrasound. They will also look at blood markers to see how they relate to the imaging results. You might be able to join if you are 18 or older, have liver cirrhosis, are already in a screening program for HCC, and can have an MRI. The study aims to enroll 820 participants.

Study design
This is an observational study comparing different imaging methods for liver cancer screening. It is a single-arm, non-randomized study planning to enroll 820 participants.
What's involved
You would undergo clinically indicated imaging-based screening for HCC, including an MRI and ultrasound. You would need to complete all study procedures within specified time windows.
Compensation
Not stated in the trial record.
Follow-up
Your clinical results from the full baseline MRI and subsequent imaging and pathology data will be collected over 6 months. Routine clinical follow-up imaging at 6 months will be observed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04539717

FAST (Focused Abbreviated Screening Technique)-MRI Study

Enrolling by Invitation
Not specifiedAges 18+Observational
Icahn School of Medicine at Mount Sinai
~820 participants
Updated 2025-10-08 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Presence of HCC
Measured over Within 6 months after initial index imaging (MRI & US)

Conditions

Hepatocellular Carcinoma (HCC)
Liver Cirrhosis

Explore related trials

CirrhosisHepatocellular Carcinoma

NCT04539717

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cedars-Sinai Medical Center

    Los Angeles, Californiano site contact published

  • Icahn School of Medicine at Mount Sinai

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bachir Taouli · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Liver cirrhosis of any etiology.
18 years of age and older.
Enrolled in screening/surveillance program for HCC.
Clinically indicated imaging-based screening for HCC.
Willing and able to complete all study procedures within specified time windows.
Patient is able to give informed consent for this study.

Exclusion

Contra-indications to MRI.
Age less than 18 years.
Patients with chronic renal failure or inability to tolerate contrast.
Inability to undergo MRI due to lack of insurance coverage.
Prior negative screening exam less than 5 months prior to enrollment.
Prior hepatic resection.
Post liver transplantation.
Previously treated HCC or other liver neoplasm.
Any other condition or factor that in judgment of study investigator may interfere with study completion.

What this trial measures

  • Presence of HCCWithin 6 months after initial index imaging (MRI & US)

    The presence of HCC will be determined by a composite reference standard. This composite reference standard incorporates the results of the complete MRI exam, pathology, and clinical follow-up.